GeneFab
GeneFab is a contract research and manufacturing organization focused on cell and gene therapies. GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities in order to accelerate the development and commercialization of genetic medicines. GeneFab capabilities spans early-stage product design, technical development and cGMP compliant production including CAR-T/CAR-NK Cells, iPSCs, engineered cell banks, lentiviral vectors, gamma-retroviral vectors, AAV, and nucleic acid. GeneFab’s technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies, and innovator-centric manufacturing platforms to accelerate novel therapies to patients in need. Across two facilities in Alameda and South San Francisco and a facility in Singapore, GeneFab employs approximately 100 employees, including experts in cell, gene, and nucleic acid therapy, CMC, analytical development, process development and synthetic biology.
